We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paradigm Genetics -- PDGM

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (92)9/20/2005 10:44:01 AM
From: Mike McFarland  Read Replies (1) of 101
Icoria shareholders will get 0.0139 share of Clinical Data common stock for each share of Icoria, the companies said in a statement.

Based on Clinical Data's closing price on Friday, the terms represent a price for Icoria of 32 cents per share, the companies said.

Shares of Icoria closed at 18 cents on Monday in over-the-counter bulletin board trade.

Clinical Data said Icoria's biomarker discovery platform is an excellent fit with its molecualr diagnostics business model.

Based on the current share price of Clinical Data and including the impact of the expected acquisition of Genaissance Pharmaceuticals Inc. (GNSC.O: Quote, Profile, Research) , Icoria shareholders will own about 7.6 percent of the combined company, the companies said.

The acquisition is expected to close late this year or in early 2006, pending approval by Icoria shareholders. (Reporting by Tuhin Kar in Bangalore)

Boy, that was a little hairy--I owned it at 17.5
cents and for several weeks was underwater.
Current price seems a perfectly good price to
give the shares up, considering gnsc at first
glance looks somewhat broke. I bought some dpii
with the proceeds, fwiw.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext